A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH
Study Overview
Status
Status
Conditions
Conditions
- Multiple Myeloma
- Amyloidosis
- Smoldering Multiple Myeloma
- Plasma Cell Leukemia
- Cryoglobulinemia
- Light Chain Deposition Disease
- Castleman's Disease
- Heavy Chain Deposition Disease
- Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Monoclonal Gammopathy of Renal Significance (MGRS)
- Monoclonal Gammopathy of Neurological Significance (MGNS)
Intervention / Treatment
Intervention / Treatment
Detailed Description
Primary
- To establish a prospective cohort of patients with PCDs in PKUFH.
- To dynamically analyze the relation between MRD status and prognosis, and the possible role of TME in PCD patients.
Secondary To collect peripheral blood, bone marrow aspirate and urine samples from PCD patients for future study, such as the tumor clone selection and evolution.
OUTLINE: PCD patients enrolled in this study will be assessed at baseline, clinical and laboratory data and biological samples be collected. Follow-up will be done at the 1, 3, 6, 12 months and then yearly after treatment.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Bo Tang, PhD
- Phone Number: 008613521776195
- Email: tangbo8809@163.com
Study Contact Backup
- Name: Yujun Dong, M.D.
- Phone Number: 008618210264969
- Email: dongy@hsc.pku.edu.cn
Study Locations
-
-
-
Beijing, China
- Recruiting
- Peking University First Hospital
-
Contact:
- Yangliu Li
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients included are those with confirmed diagnosis of PCDs and hospitalized into Peking University First Hospital (PKUFH)
- Patients of plasma cell disorders (PCDs) are recruited. PCDs include monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple myeloma; plasma cell leukemia; amyloidosis; light chain deposition disease; heavy chain deposition disease; Castleman's disease (CD); Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes syndrome; cryoglobulinemia; Monoclonal Gammopathy of Renal Significance (MGRS); Monoclonal gammopathy of neurological significance (MGNS).
- Patients are included into this cohort after signing the ICFs.
Exclusion Criteria:
Significant comorbidity may be life-threatening.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Time Frame: 10 years
|
To measure the treatment response in the cohort study of PCDs in PKUFH.The treatment response is done according to the criteria of the International Myeloma Working Group (IWMG) of 2016.
|
10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Neoplasms
- Neuromuscular Diseases
- Metabolic Diseases
- Immune System Diseases
- Peripheral Nervous System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Skin Diseases
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Precancerous Conditions
- Congenital Abnormalities
- Skin Diseases, Vascular
- Abnormalities, Multiple
- Neoplasms, Plasma Cell
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Leukemia
- Proteostasis Deficiencies
- Polyneuropathies
- Hypergammaglobulinemia
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Skin and Connective Tissue Diseases
- Hemic and Lymphatic Diseases
- Smoldering Multiple Myeloma
- Multiple Myeloma
- Castleman Disease
- Leukemia, Plasma Cell
- Amyloidosis
- Monoclonal Gammopathy of Undetermined Significance
- POEMS Syndrome
- Cryoglobulinemia
Other Study ID Numbers
Other Study ID Numbers
- PekingUFHH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.